A Win For Concert Pharmaceuticals, Inc.
Wed, Jan 22, 2020 at 05:30 PM
Concert Pharmaceuticals, Inc. (CNCE:NASDAQ) soared at $13.09, a gain of 33%. On Tue 21 Jan 20, CNCE:NASDAQ hit a New 2-Week Intraday High of $10.5. The stock appeared on our News Catalysts scanner on Wed 22 Jan 20 at 09:35 AM in the 'BIOTECH' category. From Mon 30 Dec 19, the stock recorded 57.14% Up Days and 60.00% Green Days
The share price of the company has been moving sideways in recent weeks.
About Concert Pharmaceuticals, Inc. (CNCE:NASDAQ)
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It aims to discover and develop small-molecule drugs for new treatments to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, and Alzheimer's agitation.
Top 10 Gainers:
- Genprex, Inc. (GNPX:NASDAQ), 64.35%
- Concert Pharmaceuticals, Inc. (CNCE:NASDAQ), 33.03%
- Tetraphase Pharmaceuticals, Inc. (TTPH:NASDAQ), 29.73%
- Genius Brands International, Inc. (GNUS:NASDAQ), 27.12%
- One Stop Systems, Inc. (OSS:NASDAQ), 25.85%
- Inuvo, Inc. (INUV:NYSEMKT), 23.28%
- Baudax Bio, Inc. (BXRX:NASDAQ), 21.16%
- Express, Inc. (EXPR:NYSE), 20.72%
- AgEagle Aerial Systems, Inc. (UAVS:NYSEMKT), 20.2%
- Applied Genetic Technologies Corporation (AGTC:NASDAQ), 19.52%